Dept. In vivo Pharmacology, Merz Pharmaceuticals GmbH, D - 60318 Frankfurt am Main, Germany.
Curr Top Med Chem. 2010;10(2):187-206. doi: 10.2174/156802610790411018.
Since more than one decade, metabotropic glutamate receptors have been under investigation as targets for various CNS disorders such as anxiety, pain, depression, schizpohrenia, Alzheimer's disease and Parkinson's disease. It has been shown that some mGluRs play a crucial role in cognitive processes such as learning and memory, which was initially, demonstrated using knockout mice for each receptor subtype. Later, selective pharmacological tools were developed allowing more specific examinations of the involvement of mGluR1-8 in various forms of learning and memory. Ligands for group I and II mGluRs have been proposed as promising candidates for the treatment of cognitive disorders such as schizophrenia, Fragile X syndrome, Alzheimer's and Parkinson's disease and post traumatic stress disorder, of which some have made it to clinical testing. The present paper reviews relevant data on the role of mGluRs in learning and cognition processes focusing on their utility as targets for cognition enhancement in several CNS diseases.
十多年来，代谢型谷氨酸受体一直是各种中枢神经系统疾病（如焦虑、疼痛、抑郁、精神分裂症、阿尔茨海默病和帕金森病）的研究靶点。已经表明，一些 mGluRs 在学习和记忆等认知过程中发挥着关键作用，这最初是使用针对每种受体亚型的敲除小鼠来证明的。后来，开发了选择性药理学工具，允许更具体地检查 mGluR1-8 在各种形式的学习和记忆中的参与。I 组和 II 组 mGluR 的配体被提议作为治疗认知障碍（如精神分裂症、脆性 X 综合征、阿尔茨海默病和帕金森病以及创伤后应激障碍）的有希望的候选药物，其中一些已进入临床测试。本文综述了 mGluRs 在学习和认知过程中的作用的相关数据，重点介绍了它们作为几种中枢神经系统疾病认知增强靶点的用途。
